<DOC>
	<DOCNO>NCT01848925</DOCNO>
	<brief_summary>The purpose study compare safety SANGUINATE™ versus Hydroxyurea patient suffer Sickle Cell Disease .</brief_summary>
	<brief_title>Study SANGUINATE™ Versus Hydroxyurea Sickle Cell Disease ( SCD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Patients Homozygous ( HbSS ) Sickle Cell Anemia ; Hb level : &gt; 6g/dL &lt; 10g/dL ; Age : &gt; 18 year old ; Frequency ER hospitalization &lt; 6x/yr SCD pain event document `` medical history '' . Patients , chronic transfusion program , define regular transfusion every 28 week ; Allergic Hydroxyurea ; History clinical significant disease , determine Investigator ; History allergy major allergic reaction consider clinically significant Investigator ; Screening assessment consider abnormal Investigator ; Patient sever pulmonary hypertension ( index &gt; 3 meter per sec ) ; Donated blood within 60 day screen otherwise experience blood loss &gt; 250 mL within period ; Intending begin new concomitant drug therapy overthecounter medication anytime scree4nin time administration study drug ;</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>SANGUINATE</keyword>
</DOC>